10 news items
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
TAK
9 May 24
-to-Mid 30s% Target
Takeda (TYO
Takeda Receives Positive CHMP Opinion For Fruquintinib In Previously Treated Metastatic Colorectal Cancer
TAK
26 Apr 24
− If Approved in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Regardless
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
TAK
26 Apr 24
in the European Union, Fruquintinib Will Be the First Novel Targeted Therapy for Metastatic Colorectal Cancer Regardless of Biomarker Status in Over
U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease
TAK
18 Apr 24
regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
TAK
27 Mar 24
Diseases, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We
bxi43cec77yw9py837frq813mpueiulfh4
TAK
19 Mar 24
− ICLUSIG Becomes the First and Only Targeted Treatment Approved in the U.S. for Frontline Ph+ Acute Lymphoblastic Leukemia (ALL
2eebtemovhy5ikvuyr27xqz1b5g6pe8pz6hhe40lngm5azl4xf
TAK
13 Mar 24
statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets
l47awe ln7
TAK
26 Feb 24
of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as "targets
wo95eq8c00hfr7u2b7zv99qffts fn3dj03m6dnviv4e19y7akia2u1p0a
TAK
26 Feb 24
, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies
4fvadblo1a7pa ph6gc4qpbhzu8cw7hmsexn5jmsw
TAK
13 Feb 24
efforts on four therapeutic areas: Oncology, Rare Genetics and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D
- Prev
- 1
- Next